Changes in insulin resistance following bariatric surgery and the adipoinsular axis: Role of the adipocytokines, leptin, adiponectin and resistin

Obesity Surgery

Volumn 15, Issue 5, 2005, Pages 692-699

  Ballantyne, Garth H ^a,b   Gumbs, Andrew ^b   Modlin, Irvin M ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adipocytokines; Adipoinsular axis; Adiponectin; Bariatric surgery; Biliopancreatic diversion; Gastric bypass; Insulin resistance; Laparoscopic adjustable gastric banding; Leptin; Morbid obesity; Resistin; Type 2 diabetes mellitus

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; LEPTIN; POLYPEPTIDE; RESISTIN; UNCLASSIFIED DRUG;

ADIPOINSULAR AXIS; ADULT; BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; BODY MASS; CLINICAL ARTICLE; FEMALE; GASTRIC BANDING; HUMAN; INSULA; INSULIN METABOLISM; INSULIN RELEASE; INSULIN RESISTANCE; LAPAROSCOPIC SURGERY; MALE; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; STOMACH BYPASS;

ADIPONECTIN; ANIMALS; GASTRIC BYPASS; HORMONES, ECTOPIC; HUMANS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEPTIN; OBESITY, MORBID; RESISTIN;

EID: 20544431563     PISSN: 09608923     EISSN: None     Source Type: Journal    
DOI: 10.1381/0960892053923789     Document Type: Review

References (101)

1. Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-9.
2. Flegal KM, Carrol MD, Ogden CL et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288: 1772-3.
3. Vikram NK, Misra A, Pandey RM, et al. Anthrometry and body composition in northern Asian Indian patients with type 2 diabetes: receiver operating characteristics (ROC) curve analysis of body mass index with percentage body fat as standard. Diabetes Nutr Metab 2003; 16: 32-40.
4. Wiegand S, Maikowski U, Blankenstein O et al. Type 2 diabetes and impaired glucose tolerance in European children and adolescents with obesity - a problem that is no longer restricted to minority groups. Eur J Endocrinol 2004; 151: 199-206.
5. Moller DE, Flier JS. Insulin resistance - mechanisms, syndromes, and implications. N Engl J Med 1991; 325: 646-7.
6. Pories WJ, MacDonald KG Jr, Morgan EJ et al. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr 1992; 55 (Suppl 2): 582S-585S.
7. Pories WJ, Albrecht RJ. Etiology of type II diabetes mellitus: role of the foregut. World J Surg 2001; 25: 527-31.
8. Pories WJ. Why does the gastric bypass control type 2 diabetes mellitus? Obes Surg 1992; 2: 303-14.
9. Pories WJ, Swanson MS, MacDonald KG et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995; 222: 339-350; discussion 350-332.
10. Unger RH, Eisentraut AM. Entero-insular axis. Arch Intern Med 1969; 123: 261-6.
11. Creutzfeldt W. The incretin concept today. Diabetologia 1979; 16: 75-85.
12. Preitner F, Ibberson M, Franklin I et al. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 2004; 113: 635-45.
13. Holdstock C, Engstrom BE, Ohrvall M et al. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003; 88: 3177-83.
14. Kim MS, Namkoong C, Kim HS et al. Chronic central administration of ghrelin reverses the effects of leptin. Int J Obes 2004; 27:[Epub ahead of print].
15. Patriti A, Facchiano E, Sanna A et al. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg 2004; 14: 840-8.
16. Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 2002; 236: 554-9.
17. Rubino F, Gagner M. Weight loss and plasma ghrelin levels. N Engl J Med 2002; 347: 1379-81; author reply 1379-81.
18. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 2004; 239: 12-3.
19. Türkoglu C, Duman BS, Günag D et al. Effect of abdominal obesity on insulin resistance and the components of the metabolic syndrome: evidence supporting obesity as the central feature. Obes Surg 2003; 13: 699-705.
20. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effect of modest weight loss on cardiovascular risk factors. Int J Obes 1997; 21 (Suppl): S5-S9.
21. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes 1991; 16: 397-415.
22. Faraj M, Lu HL, Cianflone K. Diabetes, lipids, and adipocyte secretagogues. Biochem Cell Biol 2004; 82: 170-9.
23. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med 2004; 255: 439-47.
24. Vendrell J, Broch M, Vilarrasa N et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004; 12: 962-71.
25. Scheen AJ. Pathophysiology of type 2 diabetes. Acta Clin Belg 2003; 58: 335-41.
26. Seufert J, Kieffer TJ, Leech CA et al. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: implications for the development of adipogenic diabetes mellitus. J Clin Endocrinol Metab 1999; 84: 670-6.
27. Seufert J, Kieffer TJ, Habener JF. Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice. PNAS 1999; 96: 674-9.
28. Das SK, Roberts SB, Kehayias JJ et al. Body composition characterization and method validation in extreme obesity and following massive weight loss induced by gastric bypass. Am J Physiol Endocrinol Metab 2003; 284: E1080-1088.
29. Gumps A, Modlin IM, Ballantyne GH. Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obes Surg 2005; 15: 462-73.
30. Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 1978; 3: 141-8.
31. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-5.
32. Staiger H, Tschritter O, Macham J et al. Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res 2003; 11: 368-72.
33. Considine RV. Leptin and obesity in humans. Eat Weight Disorder 1997; 2: 61-6.
34. Wing RR, Sinha MK, Considine RV et al. Relationship between weight loss maintenance and changes in serum leptin levels. Horm Metab Res 1996; 28: 698-703.
35. Boden G, Chen X, Mozzoli M et al. Effect of fasting on serum leptin in normal human subjects. J Clin Endocrinol Metab 1996; 81: 3419-23.
36. Boden G, Chen X, Kolaczynski JW et al. Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects. J Clin Invest 1997; 100: 1107-13.
37. Wadden TA, Considine RV, Foster GD et al. Short- and long-term changes in serum leptin in dieting obese women: effects of caloris restriction and weight loss. J Clin Endocrinol Metab 1998; 83: 214-8.
38. Nijhuis J, van Dielen FMH, Buurman WA et al. Leptin in morbidly obese patients: no role for treatment of morbid obesity but important in the postoperative immune response. Obes Surg 2004; 14: 476-83.
39. Margetic S, Gazzola C, Pegg GG et al. Leptin: a review of its peripheral actions and interactions. Int J Obes 2004; 26: 1407-33.
40. Kieffer TJ, Heller RS, Habener JF. Leptin receptors expressed on pancreatic beta-cells. Biochem Biophys Res Commun 1996; 224: 522-7.
41. Huang KC, Lin RC, Kormas N et al. Plasma leptin is associated with insulin resistance independent of age, body mass index, fat mass, lipids, and pubertal development in nondiabetic adolescents. Int J Obes 2004; 28: 470-5.
42. Abate N, Chandalia M, Snell PG et al. Adipose tissue metabolites and insulin resistance in nondiabetic Asian Indian men. J Clin Endocrinol Metab 2004; 89: 2750-5.
43. Tene Perez CE, Revilla-Monsalve MC, Amato D et al. Correlation between serum leptin levels and insulin sensitivity in diffuse toxic goiter. Endocr Res 2004; 30: 19-27.
44. Ren W, Zhang SH, Wu J et al. Polymorphism of the leptin gene promoter in pedigrees of type 2 diabetes mellitus in Chongqing, China. Chin Med J (Engl) 2004; 117: 558-61.
45. Chiu KC, Chu A, Chuang LM et al. Association of leptin receptor polymorphism with insulin resistance. Eur J Endocrinol 2004; 150: 725-9.
46. Takahashi-Yasuno A, Masuzaki H, Miyawaki T et al. Association of Ob-R gene polymorphism and insulin resistance in Japanese men. Metabolism 2004; 53: 650-4.
47. Mantzoros CS, Liolios AD, Tritos NA et al. Circulating insulin concentrations, smoking, and alcohol intake are important independent predictors of leptin in young healthy men. Obes Res 1998; 6: 179-86.
48. Haffner SM, Miettinen H, Mykkanen L et al. Leptin concentrations and insulin sensitivity in normoglycemic men. Int J Obes 1997; 21: 393-9.
49. Caro JF, Sinha MK, Kolaczynski JW et al. Leptin: the tale of an obesity gene. Diabetes 1996; 45: 1455-62.
50. Rentsch J, Chiesi M. Regulation of ob gene mRNA levels in cultured adipocytes. FEBS Lett 1996; 379: 55-9.
51. Utriainen T, Malmstrom R, Makimattila S et al. Supraphysiological hyperinsulinemia increases plasma leptin concentrations after 4 h in normal subjects. Diabetes 1996; 45: 1364-6.
52. Malmstrom R, Taskinen MR, Karonen SL et al. Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM. Diabetologia 1996; 39: 993-6.
53. Ryan AS, Elahi D. The effects of acute hyperglycemia and hyperinsulinemia on plasma leptin levels: its relationships with body fat, visceral adiposity, and age in women. J Clin Endocrinol Metab 1996; 81: 4433-8.
54. Sivitz WI, Walsh SA, Morgan DA et al. Effects of leptin on insulin sensitivity in normal rats. Endocrinology 1997; 138: 3395-401.
55. Kamohara S, Burcelin R, Halaas JL et al. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 1997; 389: 374-7.
56. Shimomura I, Hammer RE, Ikemoto S et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401: 73-6.
57. Petersen KF, Oral EA, Dufour S et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002; 109: 1345-50.
58. Muoio DM, Dohm GL, Fiedorek FT Jr et al. Leptin directly alters lipid partitioning in skeletal muscle. Diabetes 1997; 46: 1360-3.
59. Liu L, Karkanias GB, Morales JC et al. Intracerebroventricular leptin regulates hepatic but not peripheral glucose fluxes. J Biol Chem 1998; 273: 31160-7.
60. Nijhuis J, van Dielen FMH, Buurman WA et al. Ghrelin, leptin and insulin levels after restrictive surgery: a 2-year follow-up study. Obes Surg 2004; 14: 783-7.
61. Uzun H, Zengin K, Taskin M et al. Changes in leptin, plasminogen activator factor and oxidative stress in morbidly obese patients following open and laparoscopic Swedish adjustable gastric banding. Obes Surg 2004; 14: 659-65.
62. Infanger D, Baldinger R, Branson R et al. Effect of significant intermediate-term weight loss on serum leptin levels and body composition in severely obese subjects. Obes Surg 2003; 13: 879-88.
63. Molina A, Vendrell J, Gutierrez C et al. Insulin resistance, leptin and TNF-alpha system in morbidly obese women after gastric bypass. Obes Surg 2003; 13: 615-21.
64. Wauters MA, Considine RV, Yudkin JS et al. Leptin levels in type 2 diabetes: association with measures of insulin resistance and insulin secretion. Horm Metab Res 2003; 35: 92-6.
65. De Marinis L, Bianchi A, Mancini A et al. Growth hormone secretion and leptin in morbid obesity before and after biliopancreatic diversion: relationships with insulin and body composition. J Clin Endocrinol Metab 2004; 89: 174-80.
66. Hickey MS, Pories WJ, MacDonald KG Jr et al. A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? Ann Surg 1998; 227: 637-43; discussion 643-34.
67. Kellum JM, Kuemmerle JF, O'Dorisio TM et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg 1990; 211: 763-70; discussion 770-61.
68. Scopinaro N, Adami GF, Marinari GM et al. Biliopancreatic diversion. World J Surg 1998; 22: 936-46.
69. O'Brien PE, Dixon JB. Laparoscopic adjustable gastric banding in the treatment of morbid obesity. Arch Surg 2003; 138: 376-82.
70. Sirinek KR, O'Dorisio TM, Hill D et al. Hyperinsulinism, glucose-dependent insulinotropic polypeptide, and the enteroinsular axis in morbidly obese patients before and after gastric bypass. Surgery 1986; 100: 781-7.
71. Greenway SE, Greenway FL 3rd, Klein S. Effects of obesity surgery on non-insulin-dependent diabetes mellitus. Arch Surg 2002; 137: 1109-17.
72. Takahashi M, Arita Y, Yamagata K et al. Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes 2000; 24: 861-8.
73. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ et al. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 2001; 280: E827-847.
74. Maeda K, Okubo K, Shimomura I et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-9.
75. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13: 84-9.
76. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 1999; 892: 146-54.
77. Weyers C, Funahashi T, Tanaka S et al. Hypo-adiponectemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-5.
78. Yang WS, Lee WJ, Funahashi T et al. Plasma adiponectin levels in overweight and obese Asians. Obes Res 2002; 10: 1104-10.
79. English PJ, Coughlin SR, Hayden K et al. Plasma adiponectin increases postprandially in obese, but not lean, subjects. Obes Res 2003; 11: 839-44.
80. Kubota N, Terauchi Y, Yamauchi T et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277: 25863-6.
81. Hotta K, Funahashi T, Bodkin NL et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parrallel with reduced insulin sensitivity during the progression to type 2 diabetes in Rhesus monkeys. Diabetes 2001; 50: 1126-33.
82. Statnick MA, Beavers LS, Conner LJ et al. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res 2000; 1: 81-8.
83. Stefan N, Vozarova B, Funahashi T et al. Plasma Adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002; 51: 1884-8.
84. Spranger J, Kroke A, Mohlig M et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226-8.
85. Guldstrand M, Ahren B, Adamson U. Improved beta-cell function after standardized weight reduction in severely obese subjects. Am J Physiol Endocrinol Metab 2003; 284: E557-565.
86. Faraj M, Havel PJ, Phelis S et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003; 88: 1594-602.
87. Pender C, Goldfine ID, Tanner CJ et al. Muscle insulin receptor concentrations in obese patients post bariatric surgery: relationship to hyperinsulinemia. Int J Obes 2004; 28: 363-9.
88. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001/01/18/print 2001; 409 (6818):307-12.
89. Steppan CM, Brown EJ, Wright CM et al. A family of tissue-specific resistin-like molecules. PNAS 2001; 98: 502-6.
90. Way JM, Gorgun CZ, Tong Q et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator- activated receptor gamma agonists. J Biol Chem 2001; 276: 25651-3.
91. Chen XD, Lei T, Xia T et al. Increased expression of resistin and tumour necrosis factor in pig adipose tissue as well as effect of feeding treatment on resistin and cAMP pathway. Diabetes Obes Metab 2004; 6: 271-9.
92. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003; 88: 5452-5.
93. Mattevi VS, Zembruzuski VM, Hutz MH. A resistin gene polymorphism is associated with body mass index in women. Human Genet 2004; 115: 208-212.
94. Stejskal D, Adamovska S, Bartek J et al. Resistin - concentrations in persons with type 2 diabetes mellitus and in individuals with acute inflammatory diiseases. Biomed Papers 2003; 147: 63-9.
95. Furuhashi M, Ura N, Higashiura K et al. Circulating resistin levels in essential hypertension. Clin Endocrinol (Oxf) 2003; 59: 507-10.
96. McTernan PG, Fisher FM, Valsamakis G et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003; 88: 6098-106.
97. Satoh H, Nguyen MTA, Miles PDG et al. Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats. J Clin Invest 2004; 114: 224-31.
98. Volarova de Courten B, Degawa-Yamauchi M, Considine RV et al. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 2004; 53: 1279-84.
99. Pfutzner A, Langenfeld M, Kunt T et al. Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab 2003; 49: 571-6.
100. Silha JV, Krsek M, Skrha JV et al. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003; 149: 331-5.
101. Heilbronn LK, Rood J, Janderova L et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 2004; 89: 1844-8.